June 19, 2020
MSD’s immuno-oncology agent Keytruda (pembrolizumab) notched up growth of 64% in Japan in FY2019 as its NHI price-based sales reached 128.4 billion yen, crossing the 100 billion yen mark together with Pfizer’s pain med Lyrica (pregabalin), a Jiho tally shows...read more